Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

NCT07132528 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SOX plus PD-1 inhibitor
DRUG: SOX Chemotherapy

Sponsor

Liaoning Cancer Hospital & Institute